Kalvista Net Debt vs Capital Surpluse Analysis

KALV Stock

USD 12.04 0.45 3.60%

Kalvista Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kalvista Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kalvista Pharmaceuticals is a good investment. Please check the relationship between Kalvista Pharmaceuticals Net Debt and its Capital Surpluse accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

Net Debt vs Capital Surpluse

Net Debt vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kalvista Pharmaceuticals Net Debt account and Capital Surpluse. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kalvista Pharmaceuticals' Net Debt and Capital Surpluse is -0.49. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Kalvista Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kalvista Pharmaceuticals' Net Debt and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Kalvista Pharmaceuticals are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Debt i.e., Kalvista Pharmaceuticals' Net Debt and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

-0.49

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Capital Surpluse

Most indicators from Kalvista Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kalvista Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.Issuance Of Capital Stock is likely to climb to about 58.6 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.6 M in 2024.

	2023	2024 (projected)
Net Interest Income	2.6M	2.7M
Non Recurring	1.3M	1.2M

Net Interest Income Non Recurring

Kalvista Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Assets	Long Term Debt
Total Assets		0.5	0.85	0.47	0.99	0.63	0.4	-0.6	-0.81	0.77	0.58	0.62	-0.22	1.0	0.74	0.64	-0.6	0.83	0.91	-0.3	0.89	1.0	-0.55	0.74	-0.09	0.33
Short Long Term Debt Total	0.5		0.38	-0.06	0.5	0.57	-0.23	-0.06	-0.65	0.51	0.22	0.6	0.36	0.49	0.48	0.4	0.04	0.53	0.49	-0.21	0.63	0.48	0.29	0.47	0.53	0.46
Other Current Liab	0.85	0.38		0.64	0.85	0.36	0.36	-0.44	-0.89	0.85	0.46	0.36	-0.32	0.81	0.65	0.43	-0.56	0.87	0.95	-0.2	0.91	0.85	-0.52	0.67	-0.05	0.32
Total Current Liabilities	0.47	-0.06	0.64		0.43	0.16	0.52	-0.56	-0.47	0.59	0.46	0.16	-0.23	0.44	0.33	0.28	-0.37	0.48	0.53	0.1	0.49	0.47	-0.52	0.34	-0.05	-0.14
Total Stockholder Equity	0.99	0.5	0.85	0.43		0.64	0.44	-0.61	-0.8	0.78	0.62	0.63	-0.14	0.99	0.78	0.65	-0.67	0.83	0.89	-0.43	0.87	0.99	-0.57	0.79	-0.02	0.31
Property Plant And Equipment Net	0.63	0.57	0.36	0.16	0.64		0.43	-0.66	-0.62	0.66	0.55	1.0	0.15	0.62	0.73	0.97	-0.47	0.54	0.49	-0.42	0.58	0.62	-0.36	0.71	0.27	0.18
Current Deferred Revenue	0.4	-0.23	0.36	0.52	0.44	0.43		-0.81	-0.32	0.45	0.58	0.41	-0.2	0.39	0.42	0.56	-0.71	0.32	0.37	-0.43	0.29	0.4	-0.82	0.42	-0.15	-0.59
Net Debt	-0.6	-0.06	-0.44	-0.56	-0.61	-0.66	-0.81		0.5	-0.6	-0.87	-0.64	0.13	-0.61	-0.69	-0.73	0.72	-0.34	-0.48	0.33	-0.45	-0.61	0.76	-0.68	-0.01	0.28
Retained Earnings	-0.81	-0.65	-0.89	-0.47	-0.8	-0.62	-0.32	0.5		-0.92	-0.52	-0.62	0.22	-0.77	-0.76	-0.61	0.48	-0.87	-0.93	0.21	-0.97	-0.8	0.4	-0.76	-0.13	-0.33
Accounts Payable	0.77	0.51	0.85	0.59	0.78	0.66	0.45	-0.6	-0.92		0.6	0.66	-0.08	0.73	0.81	0.7	-0.61	0.82	0.83	-0.35	0.86	0.76	-0.53	0.81	0.24	0.23
Cash	0.58	0.22	0.46	0.46	0.62	0.55	0.58	-0.87	-0.52	0.6		0.53	0.02	0.6	0.85	0.58	-0.77	0.33	0.44	-0.42	0.46	0.59	-0.66	0.85	0.17	-0.06
Non Current Assets Total	0.62	0.6	0.36	0.16	0.63	1.0	0.41	-0.64	-0.62	0.66	0.53		0.22	0.61	0.71	0.96	-0.43	0.54	0.48	-0.44	0.57	0.61	-0.31	0.69	0.33	0.18
Non Currrent Assets Other	-0.22	0.36	-0.32	-0.23	-0.14	0.15	-0.2	0.13	0.22	-0.08	0.02	0.22		-0.21	0.04	0.08	0.15	-0.27	-0.39	-0.52	-0.3	-0.23	0.43	0.02	0.89	-0.03
Cash And Short Term Investments	1.0	0.49	0.81	0.44	0.99	0.62	0.39	-0.61	-0.77	0.73	0.6	0.61	-0.21		0.73	0.62	-0.6	0.79	0.88	-0.3	0.86	1.0	-0.54	0.73	-0.1	0.32
Common Stock Total Equity	0.74	0.48	0.65	0.33	0.78	0.73	0.42	-0.69	-0.76	0.81	0.85	0.71	0.04	0.73		0.75	-0.81	0.63	0.64	-0.56	0.7	0.74	-0.62	1.0	0.24	0.31
Common Stock Shares Outstanding	0.64	0.4	0.43	0.28	0.65	0.97	0.56	-0.73	-0.61	0.7	0.58	0.96	0.08	0.62	0.75		-0.59	0.56	0.51	-0.46	0.56	0.63	-0.52	0.73	0.2	0.13
Non Current Liabilities Total	-0.6	0.04	-0.56	-0.37	-0.67	-0.47	-0.71	0.72	0.48	-0.61	-0.77	-0.43	0.15	-0.6	-0.81	-0.59		-0.49	-0.49	0.65	-0.45	-0.61	0.92	-0.81	0.08	0.04
Other Current Assets	0.83	0.53	0.87	0.48	0.83	0.54	0.32	-0.34	-0.87	0.82	0.33	0.54	-0.27	0.79	0.63	0.56	-0.49		0.91	-0.2	0.93	0.83	-0.44	0.64	-0.08	0.36
Other Stockholder Equity	0.91	0.49	0.95	0.53	0.89	0.49	0.37	-0.48	-0.93	0.83	0.44	0.48	-0.39	0.88	0.64	0.51	-0.49	0.91		-0.15	0.97	0.9	-0.48	0.66	-0.13	0.31
Total Liab	-0.3	-0.21	-0.2	0.1	-0.43	-0.42	-0.43	0.33	0.21	-0.35	-0.42	-0.44	-0.52	-0.3	-0.56	-0.46	0.65	-0.2	-0.15		-0.13	-0.3	0.38	-0.55	-0.49	0.09
Property Plant And Equipment Gross	0.89	0.63	0.91	0.49	0.87	0.58	0.29	-0.45	-0.97	0.86	0.46	0.57	-0.3	0.86	0.7	0.56	-0.45	0.93	0.97	-0.13		0.88	-0.4	0.7	-0.02	0.38
Total Current Assets	1.0	0.48	0.85	0.47	0.99	0.62	0.4	-0.61	-0.8	0.76	0.59	0.61	-0.23	1.0	0.74	0.63	-0.61	0.83	0.9	-0.3	0.88		-0.56	0.74	-0.1	0.33
Short Term Debt	-0.55	0.29	-0.52	-0.52	-0.57	-0.36	-0.82	0.76	0.4	-0.53	-0.66	-0.31	0.43	-0.54	-0.62	-0.52	0.92	-0.44	-0.48	0.38	-0.4	-0.56		-0.61	0.36	0.22
Common Stock	0.74	0.47	0.67	0.34	0.79	0.71	0.42	-0.68	-0.76	0.81	0.85	0.69	0.02	0.73	1.0	0.73	-0.81	0.64	0.66	-0.55	0.7	0.74	-0.61		0.23	0.33
Other Assets	-0.09	0.53	-0.05	-0.05	-0.02	0.27	-0.15	-0.01	-0.13	0.24	0.17	0.33	0.89	-0.1	0.24	0.2	0.08	-0.08	-0.13	-0.49	-0.02	-0.1	0.36	0.23		0.04
Long Term Debt	0.33	0.46	0.32	-0.14	0.31	0.18	-0.59	0.28	-0.33	0.23	-0.06	0.18	-0.03	0.32	0.31	0.13	0.04	0.36	0.31	0.09	0.38	0.33	0.22	0.33	0.04

Click cells to compare fundamentals

Kalvista Pharmaceuticals Account Relationship Matchups

Kalvista Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.1M	92.5M	272.0M	203.9M	183.2M	88.7M
Short Long Term Debt Total	54K	1.6M	5.9M	8.2M	8.2M	4.6M
Other Current Liab	5.5M	6.9M	7.0M	9.1M	29K	27.6K
Total Current Liabilities	18.1M	7.7M	9.8M	11.6M	15.0M	4.1M
Total Stockholder Equity	96.7M	83.8M	257.2M	185.1M	161.0M	66.4M
Property Plant And Equipment Net	3.7M	7.5M	10.0M	10.8M	12.4M	13.0M
Net Debt	(14.1M)	(44.7M)	(22.5M)	(48.0M)	(43.2M)	(41.0M)
Retained Earnings	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)	(76.3M)
Accounts Payable	2.9M	1.7M	2.0M	3.6M	4.8M	2.0M
Cash	32.0M	15.8M	50.6M	30.7M	56.2M	32.8M
Non Current Assets Total	3.8M	7.7M	10.2M	10.9M	12.5M	13.1M
Cash And Short Term Investments	100.8M	67.7M	248.9M	166.2M	149.4M	77.5M
Common Stock Total Equity	17K	18K	24K	25K	34K	18.2K
Common Stock Shares Outstanding	17.7M	19.1M	24.5M	27.9M	32.1M	33.7M
Liabilities And Stockholders Equity	92.5M	272.0M	203.9M	183.2M	210.7M	221.2M
Non Current Liabilities Total	1.1M	5.0M	7.2M	7.1M	6.4M	11.2M
Other Current Assets	4.5M	4.9M	10.6M	6.4M	1.0M	959.5K
Other Stockholder Equity	207.2M	426.4M	439.1M	507.1M	(75K)	(71.3K)
Total Liab	21.4M	8.8M	14.8M	18.8M	22.2M	7.1M
Property Plant And Equipment Gross	2.4M	3.7M	7.5M	10.0M	10.8M	764.8K
Total Current Assets	115.5M	88.7M	264.3M	193.6M	172.3M	85.2M
Accumulated Other Comprehensive Income	(1.9M)	(1.9M)	(1.4M)	(3.9M)	(3.1M)	(659.4K)
Short Term Debt	54K	588K	863K	977K	1.1M	1.2M
Common Stock	17K	18K	24K	25K	34K	15.9K
Capital Surpluse	191.1M	207.2M	426.4M	439.1M	507.1M	115.8M
Property Plant Equipment	2.4M	2.0M	1.8M	2.2M	2.9M	1.3M
Net Tangible Assets	83.8M	257.2M	185.1M	161.0M	43.1M	40.9M
Net Receivables	11.3M	16.5M	10.4M	14.1M	16.6M	2.1M
Retained Earnings Total Equity	(71.7M)	(92.5M)	(121.6M)	(167.8M)	(250.2M)	(343.1M)
Net Invested Capital	83.8M	257.2M	185.1M	161.0M	185.2M	132.4M
Net Working Capital	81.0M	254.5M	182.1M	157.3M	180.9M	132.0M
Capital Lease Obligations	1.6M	5.9M	8.2M	8.2M	9.5M	9.9M
Capital Stock	18K	24K	25K	34K	39.1K	26.0K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kalvista Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kalvista Pharmaceuticals' short interest history, or implied volatility extrapolated from Kalvista Pharmaceuticals options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Kalvista Pharmaceuticals is a strong investment it is important to analyze Kalvista Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Kalvista Pharmaceuticals' future performance. For an informed investment choice regarding Kalvista Stock, refer to the following important reports:

How To Invest In Kalvista

Details

Is Kalvista Stock a good investment?

Details

What is Kalvista Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kalvista Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Kalvista Stock please use our How to Invest in Kalvista Pharmaceuticals guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Kalvista Stock analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Transaction History View history of all your transactions and understand their impact on performance
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Volatility Analysis Get historical volatility and risk analysis based on latest market data

Is Kalvista Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kalvista Pharmaceuticals. If investors know Kalvista will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kalvista Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.12)

Revenue Per Share

0.214

Quarterly Revenue Growth

0.307

Return On Assets

(0.42)

Return On Equity

(0.79)

The market value of Kalvista Pharmaceuticals is measured differently than its book value, which is the value of Kalvista that is recorded on the company's balance sheet. Investors also form their own opinion of Kalvista Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kalvista Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kalvista Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kalvista Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kalvista Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kalvista Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kalvista Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kalvista Net Debt vs Capital Surpluse Analysis

Net Debt vs Capital Surpluse

Net Debt vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Net Debt

Capital Surpluse

Kalvista Pharmaceuticals fundamental ratios Correlations

Kalvista Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kalvista Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Kalvista Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.93	Retained Earnings
Accounts Payable	- 0.92	Retained Earnings
Retained Earnings	- 0.89	Other Current Liab
Other Current Assets	- 0.87	Retained Earnings
Cash	- 0.87	Net Debt